天演药业上涨4.39%，报2.38美元/股，总市值1.12亿美元

Core Viewpoint - Tianyan Pharmaceutical (ADAG) is a biopharmaceutical company focused on developing innovative cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceutical reported total revenue of $103,200, a year-over-year decrease of 99.43% [1]. - The company recorded a net profit attributable to shareholders of -$33.4241 million, representing a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceutical is a platform-driven company engaged in the clinical product development phase, dedicated to discovering and developing new cancer immunotherapies [1]. - The company’s antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, aiming to create potentially innovative or best-in-class products globally [1].